Cision PR Newswire

RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS

From RPO and Romomo to PartyOS, RoboParty is building an open humanoid robotics foundation for developers worldwide. PITTSBURGH, Oct. 4, 2026 /PRNewswire/ -- On September 28, 2026, RoboParty publicly unveiled RP1 (ROBOTO 01) at IROS 2026, marking the robot's global debut. In January 2026, RoboParty fully open-sourced RPO...

RoboParty Unveils RP1, a High-Performance Full-Stack Open-Source Humanoid Robot at IROS

PITTSBURGH, Oct. 3, 2026 /PRNewswire/ -- On September 28, 2026, RoboParty publicly unveiled RP1 (ROBOTO...

‘Global Civilization Dialogues’ Series Arrives in Xi’an with Orchid Awards Guests

XI'AN, China, Sept. 30, 2026 /PRNewswire/ -- An international exchange event in the "Global...

Govee Turns Up the Spooky With Sarah Michelle Gellar in New Nationwide Halloween Campaign

The horror screen icon stars in Govee's "Turn Up the Spooky. Slay Halloween." outdoor...

Dingdong (Cayman) Limited Announces Fourth Quarter 2024 Financial Results

SHANGHAI, March 6, 2025 /PRNewswire/ -- Dingdong (Cayman) Limited ("Dingdong" or the "Company") (NYSE: DDL), a leading fresh grocery e-commerce company in China, with advanced...

Dingdong Announces US$20.0 Million Share Repurchase Program

SHANGHAI, March 6, 2025 /PRNewswire/ -- Dingdong (Cayman) Limited ("Dingdong" or the "Company") (NYSE: DDL), leading fresh grocery e-commerce company in China, today announced that...

ATFX Appoints Mohammad Aladham as Managing Director for Southeast Asia to Drive Regional Growth

HONG KONG, March 6, 2025 /PRNewswire/ -- ATFX, a global leader in online trading, proudly announces the appointment of Mohammad Aladham as the new...

GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a Globally First-in-Class Base Editing Drug for Duchenne Muscular Dystrophy

SUZHOU, China, March 6, 2025 /PRNewswire/ -- On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is...